Primary and secondary CNS lymphoma demographics and pretreatment data
| PCNSL . | . | SCNSL . | . |
|---|---|---|---|
| Patients (n) | 30 | Patients (n) | 98 |
| Median age, y (range) | 56 (44.5-67) | Median age, y (range) | 50 (38-58) |
| Cell-of-origin, n (% of documented cases) | Histology | ||
| non-GCB | 15 (93.75) | DLBCL (GCB, non-GCB, NOS, HGBCL) | 91 |
| GCB n (%) | 1 (6.25) | Transformed follicular lymphoma | 3 |
| NR | 14 | Primary mediastinal B-cell lymphoma | 2 |
| Intravascular large B-cell lymphoma | 1 | ||
| Post-transplant lymphoproliferative disorder | 1 | ||
| Prior lines of therapy, median (range) | 3.75 (3-5) | Prior lines of therapy, median (range) | 4 (3-7) |
| CAR Product, costimulatory domain n (%) | CAR Product, costimulatory domain n, (%) | ||
| axi-cel, CD28 | 2 (6.67) | axi-cel, CD28 | 50 (51.02) |
| tisa-cel, 4-1BB | 19 (63.33) | tisa-cel, 4-1BB | 12 (12.24) |
| Trial anti-CD19, CD28 | 5 (16.67) | liso-cel, 4-1BB | 7 (7.14) |
| Trial anti-CD19 + anti-CD22 | 4 (13.33) | Other | 29 (29.59) |
| Bridging therapy | Bridging therapy, n (%) | ||
| Yes | 24 | Yes | 30 (30.61) |
| No | 2 | No | 7 (7.14) |
| Allowed, but NR | 4 | Allowed, but NR | 15 (15.30) |
| NR | 46 (46.94) | ||
| Conditioning therapy, n (%) | Conditioning therapy, n (%) | ||
| FC | 26 (86.67) | FC | 66 (63.35) |
| Other | 4 (13.33) | Other | 10 (10.20) |
| NR | 22 (22.45) |
| PCNSL . | . | SCNSL . | . |
|---|---|---|---|
| Patients (n) | 30 | Patients (n) | 98 |
| Median age, y (range) | 56 (44.5-67) | Median age, y (range) | 50 (38-58) |
| Cell-of-origin, n (% of documented cases) | Histology | ||
| non-GCB | 15 (93.75) | DLBCL (GCB, non-GCB, NOS, HGBCL) | 91 |
| GCB n (%) | 1 (6.25) | Transformed follicular lymphoma | 3 |
| NR | 14 | Primary mediastinal B-cell lymphoma | 2 |
| Intravascular large B-cell lymphoma | 1 | ||
| Post-transplant lymphoproliferative disorder | 1 | ||
| Prior lines of therapy, median (range) | 3.75 (3-5) | Prior lines of therapy, median (range) | 4 (3-7) |
| CAR Product, costimulatory domain n (%) | CAR Product, costimulatory domain n, (%) | ||
| axi-cel, CD28 | 2 (6.67) | axi-cel, CD28 | 50 (51.02) |
| tisa-cel, 4-1BB | 19 (63.33) | tisa-cel, 4-1BB | 12 (12.24) |
| Trial anti-CD19, CD28 | 5 (16.67) | liso-cel, 4-1BB | 7 (7.14) |
| Trial anti-CD19 + anti-CD22 | 4 (13.33) | Other | 29 (29.59) |
| Bridging therapy | Bridging therapy, n (%) | ||
| Yes | 24 | Yes | 30 (30.61) |
| No | 2 | No | 7 (7.14) |
| Allowed, but NR | 4 | Allowed, but NR | 15 (15.30) |
| NR | 46 (46.94) | ||
| Conditioning therapy, n (%) | Conditioning therapy, n (%) | ||
| FC | 26 (86.67) | FC | 66 (63.35) |
| Other | 4 (13.33) | Other | 10 (10.20) |
| NR | 22 (22.45) |
non-GCB, non-germinal center B-cell origin; GCB, germinal center B-cell origin; NOS, not otherwise specified; HGBCL, high grade B-cell lymphoma; axi-cel, axicabtagene ciloleucel; tisa-cel, tisagenlecleucel; liso-cel, lisocabtagene ciloleucel; NR, not recorded; FC, fludarabine-cyclophosphamide.